SXTP Stock — 60 Degrees Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$0.96

Market cap

$3.4M

Cash

$1.0M

Enterprise value

$2.5M

Balance sheet

Cash	$1.0M
Debt	$0.1M
Net cash	$0.9M
Enterprise value	$2.5M
Basic shares	2.7M shares
Fully diluted shares	3.5M shares
Fully diluted market cap	$3.4M
Cash per share	$0.38

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading SXTP daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Mar 15 - Apr 26	Tafenoquine 100mg	Phase 2	Chronic Babesiosis	—
Apr 12 - May 24	Tafenoquine	Phase 2	Babesiosis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Tafenoquine (Arakoda regimen)

Approved · Active Modality: small molecule (8-aminoquinoline; oral)

Partnerships Licensed from the U.S. Army (USAMMDA), covering all therapeutic uses except radical cure of symptomatic vivax malaria; cooperative R&D agreement with the U.S. Army supporting original Arakoda NDA. Babesiosis use licensed from Tufts Medical Center (Dec 2024)

Indications

Malaria prevention (Approved)
Babesiosis (hospitalized patients, with standard of care) (Phase 2)
Canine babesiosis / equine Theileria (veterinary) (Preclinical)

Catalysts

— September 30, 2026

Status note Arakoda FDA-approved 2018 for malaria prevention. Double-blind, placebo-controlled trial (NCT06207370) of the Arakoda regimen with standard of care in hospitalized babesiosis patients: first patient randomized June 25, 2024; 19 patients completed. Veterinary pilot studies (canine babesiosis at NC State; equine Theileria) in planning.

Celgosivir

Preclinical · Active Modality: small molecule (host-targeted glucosidase inhibitor)

Target host alpha-glucosidases (glucosidase inhibition)

Partnerships Licensed from National University of Singapore / Singapore Health Services (patent rights for celgosivir dosing regimens for dengue)

Indications

Dengue fever (Preclinical)
Respiratory viruses (COVID-19, RSV) (Preclinical)

Status note Prior Phase II development by other sponsors (HIV, hepatitis C, dengue in 700+ patients; dengue trial showed safety with sub-powered viral-load reduction). No active company-sponsored clinical development; company holds dengue dosing patents and filed/licensed patents for respiratory virus applications.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Tafenoquine 100mg
Lead indication	Chronic Babesiosis
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06656351	Phase 2	Recruiting	Sponsor	60 Degrees Pharmaceuticals LLC	—	Chronic Babesiosis	—
NCT06207370	Phase 2	Recruiting	Sponsor	60 Degrees Pharmaceuticals LLC	—	Babesiosis	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for 60 Degrees Pharmaceuticals LLC on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

SXTP — 60 Degrees Pharmaceuticals Inc.